90 results about "Serology" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine in evaluating Kawasaki disease and treating effect thereof and application of a phenylalanine inhibitor in treating Kawasaki disease. According to serum non-targeted metabonomics analysis and verification of KD children and IVIG treated KD children, phenylalanine is highly expressed in KD children, and phenylalanine is remarkably reduced after IVIG treatment of KD and tends to healthy children. The phenylalanine can be used as a serological marker for evaluating the Kawasaki disease treatment effect and diagnosing IVIG second-line treatment, and is high in specificity and sensitivity. After the phenylalanine inhibitor is administered to a KD model mouse, the content of phenylalanine in serum is remarkably reduced and is consistent with the trend in serum of the KD mouse treated by IVIG, myrica tongues are remarkably relieved, arterial dilatation is slowed down, and expression of inflammatory factors is reduced. The phenylalanine inhibitor has the effects of treating Kawasaki disease, improving myrica rubra tongue and slowing down arterial dilatation.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The invention relates to the technical field of medical auxiliary diagnosis, and particularly discloses an auxiliary diagnosis method for multifocal motor neuropathy and peingshan disease, which comprises the following steps: step S100: performing electromyogram detection, serological examination and muscle biopsy on an examined object to obtain electromyogram signal data, serological examination result data and muscle biopsy result data; s200, performing feature extraction on the electromyogram signal data, the serological examination result data and the muscle biopsy result data, and combining the extracted features to form a feature vector; step S300, obtaining output classification probabilities, wherein the classification probabilities correspond to the multi-focus motor neuropathy and the Pingshan disease, and excluding three categories of the multi-focus motor neuropathy and the Pingshan disease; electromyogram signals, serological examination and muscle biopsy multi-source data are fused to extract core features, a classification model is constructed by using a random forest or XGBoost algorithm, and the automation and standard unification of the whole diagnosis process are realized.

The application belongs to the field of biotechnology detection, and particularly relates to a multiplex PCR detection kit for identifying and distinguishing chicken pullorum salmonella and chicken typhoid salmonella. The kit comprises stn gene detection primers, I137_14445 gene detection primers and ybgL gene detection primers. The kit can quickly, high-throughput and accurately identify and distinguish chicken pullorum salmonella and chicken typhoid salmonella, can replace traditional salmonella serological typing and biochemical identification and other complex procedures, and provides a simple, rapid, reproducible new method for monitoring and laboratory diagnosis of chicken pullorum salmonella and chicken typhoid salmonella.

This invention relates to the field of biotechnology, and aims to provide a monoclonal antibody 7A12 for identifying genotype 2 classical swine fever, along with its preparation and application methods. This monoclonal antibody contains an Ig domain V of the antibody heavy chain. H CDR1, V H CDR2 and V H CDR3, and the Ig domain V of the antibody light chain L CDR1, V L CDR2 and V L CDR3; wherein, the V H CDR1, V H CDR2 and V H The amino acid sequences of CDR3 are shown in SEQ ID NO:1-3, respectively; the V L CDR1, V L CDR2 and V L The amino acid sequences of CDR3 are shown in SEQ ID NO:4-6. The antibody provided by this invention has advantages such as high titer, strong specificity, and high affinity; it also has high sensitivity and specificity, and shows no cross-reactivity with type 1 classical swine fever vaccine strains. Serologically, it can differentiate and diagnose infection and vaccine immunization with genotype 2 classical swine fever wild-type strains. Furthermore, it can be used to develop a blocking ELISA kit for identifying genotype 2 classical swine fever, effectively diagnosing and purifying genotype 2 classical swine fever virus.

The invention belongs to the technical field of biology, and particularly relates to a detection method of a tumor serological marker. The application of the reagent for detecting the concentration of the sGRP78 protein in the serum of the breast cancer patient in preparation of a product for evaluating the curative effect of the breast cancer patient after neoadjuvant therapy is characterized in that the number of neoadjuvant therapy is four. In order to overcome the defects of dynamic monitoring deficiency, invasiveness, high cost and insufficient serum marker sensitivity in the existing neoadjuvant therapy metaphase evaluation of the breast cancer, the invention provides a detection kit, namely, the serum marker sGRP78 is monitored in the neoadjuvant therapy metaphase evaluation of the breast cancer, and the sensitivity of the serum marker sGRP78 in the neoadjuvant therapy metaphase evaluation of the breast cancer is improved. Therefore, a noninvasive, low-cost, high-sensitivity and high-specificity neoadjuvant therapy metaphase evaluation index is achieved.

The present disclosure relates to single-chain antibodies that specifically bind to the cotton leafroll dwarf virus (CLRDV), and methods for using such antibodies in the serological or molecular detection of CLRDV in plant or aphid samples. In particular, the disclosure relates to single-chain antibodies that recognize the CLRDV coat protein (CP) or the CLRDV n-terminal read-through domain (NRTD).

The invention provides a polysaccharide antigen derived from salmonella pullorum and marked by fluorescent molecules as well as a preparation method and application of the polysaccharide antigen. The invention provides a simple, convenient and rapid extraction method of the salmonella pullorum polysaccharide antigen, and the polysaccharide antigen for bacterial serological detection is prepared by combining fluorescence labeling on the basis of the experimental principle of fluorescence polarization. The polysaccharide antigen prepared according to the method provided by the invention can be used for serological detection of salmonella pullorum and has good sensitivity, and a new method is provided for detection of salmonella pullorum infection.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The application discloses application of a reagent for detecting a biomarker in preparation of a product for predicting ulcerative colitis disease activity or a product for diagnosing ulcerative colitis disease, and relates to the technical field of serological markers of inflammatory bowel disease. The serum CD105 of a UC patient is significantly higher than that of a healthy control group, and CD105 has a very high effect of diagnosing ulcerative colitis disease, and CD105 can distinguish disease activity from remission. Therefore, the application provides a novel serum marker which is convenient to sample, has good repeatability and can objectively reflect the colon mucosa inflammation load, and is expected to provide more accurate marker selection for UC disease activity prediction and UC diagnosis.

The invention discloses a diagnostic method based on mouse lyme disease serology indirect ELISA laboratory, and relates to the technical field of immunoserology detection.The diagnostic method comprises the steps that experimental conditions are optimized through a system, and the optimal reaction system is determined as follows: the antigen coating concentration is 0.2 microgram / microliter, the serum dilution ratio is 1: 200, and the enzyme-labeled secondary antibody concentration is 1: 2000. 0.8), and meanwhile, the antigen dosage is obviously reduced. Dynamic analysis of the antibody shows that the level of the antibody infecting mouse serum reaches a peak 12-25 days after inoculation, and the threshold value of the specific antibody ratio (ArB%) is 71.43%. Researches prove that the method has the characteristics of simplicity and convenience in operation, economy and high efficiency, and is suitable for primary laboratories and large-scale screening. The method provides reliable standardized technical support for lyme disease laboratory diagnosis and epidemiological monitoring.

The present invention discloses a broad-spectrum neutralizing monoclonal antibody against classical swine fever virus and its application, belonging to the field of immunoglobulins. Specifically, an antibody or its antigen-binding fragment is disclosed, which comprises a heavy-chain variable region and a light-chain variable region; the amino acid sequences of CDR1, CDR2, and CDR3 in the heavy-chain variable region sequentially comprise positions 9-15, 33-40, and 79-90 of SEQ ID No.1; the amino acid sequences of CDR1, CDR2, and CDR3 in the light-chain variable region sequentially comprise positions 21-31, 49-51, and 88-97 of SEQ ID No.3. The monoclonal antibody of the present invention can specifically react with all genotype strains of classical swine fever virus, and the established blocking ELISA method using it can detect classical swine fever virus E2 antibody. The monoclonal antibody of the present invention can be used for the identification of CSFV antigen and the development of serological antibody detection kits, providing antibody resources for the accurate diagnosis, prevention, control, and purification of CSFV.

The present application relates to the technical field of medical data mining, in particular to a whole-course management system based on fusion analysis of hepatitis B serological and virological indexes, which comprises a serum index collection module, an evolution path construction module, a characteristic section extraction module, an intervention response classification module and a fusion structure induction module.In the present application, based on the index sequence matrix formed by continuous sampling, the trend trajectory is generated by tracking the change direction of the index concentration at each time node, the change fragments with structural differences are extracted in combination with the biochemical response markers, the index combination relationship under different interventions is classified and arranged, the matching mapping between the intervention behavior and the response path is established, the regular characteristics of the intervention effect are reflected through the combination of multiple indexes, and then the induction analysis result set covering the whole treatment process is generated, thereby providing clear data basis for dynamic intervention evaluation and treatment path adjustment.

The invention discloses a pancreatic cancer diagnosis marker and application thereof, and belongs to the technical field of biological medicines, a serological marker for pancreatic cancer diagnosis is thymosin beta-10, namely Tbeta10, a biomarker for pancreatic cancer diagnosis is a gene TMSB10 for coding the Tbeta10, the gene is 9168 in an NCBI database, a qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, a qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2, the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.1, the qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, and the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2. Tbeta10 protein or TMSB10 gene high expression serves as a biomarker for diagnosis and poor prognosis of a pancreatic cancer patient, it is determined that the content of Tbeta10 in serum of the pancreatic cancer patient is remarkably increased, the Tbeta10 protein or TMSB10 gene high expression serves as a serum marker for diagnosis and curative effect and prognosis monitoring of the pancreatic cancer, and the total survival rate of the pancreatic cancer patient is reduced; the TMSB10 is used as a biomarker for poor prognosis of pancreatic cancer patients.

The invention discloses an osteonecrosis early diagnosis kit based on blood detection and a biomarker, and the osteonecrosis early diagnosis kit can be used for early diagnosis of osteonecrosis through multi-omics screening based on femoral head necrosis lesion division, serological analysis of different stages of cases and cell and animal level biological tests in combination with actual detection result verification. It is determined that a group of biomolecules, namely PEBP1, ACAT1, MMP2, SOD1 and FN1 proteins, can be used for early diagnosis of osteonecrosis.

The present invention provides a method and system for evaluating the response after liver tumor intervention based on a generative adversarial network. A method for evaluating the response after liver tumor intervention based on a generative adversarial network includes the following steps: S1. Training a deep learning model to obtain an evaluation model capable of giving a prognosis evaluation result; S2. The evaluation model takes the plain CT scan after liver surgery and the postoperative serological test information as inputs and outputs a prognosis evaluation result. The present invention does not require liver puncture, which can reduce the trauma risk and medical resources for patient prognosis estimation; after the operation, the patient of the present invention does not need to take enhanced CT, and there will be no radiation risk and medical resource consumption caused by taking enhanced CT. At the same time, it can give a prognosis evaluation result based on enhanced CT, ensuring that the CT image used as the evaluation basis can clearly show the lesion, having the effect of enhanced CT, and being able to give a more accurate evaluation result.

The invention belongs to the technical field of biology, and particularly relates to a bispecific antibody targeting African swine fever virus and hog cholera virus and application of the bispecific antibody, the bispecific antibody shows high binding capacity to p30 protein of the African swine fever virus and E2 protein of the hog cholera virus, and it is indicated that the bispecific antibody can recognize the African swine fever virus and the hog cholera virus at the same time. When the bispecific antibody disclosed by the invention is used for preparing a detection product, double-flux detection of screening African swine fever viruses and swine fever viruses can be realized at the same time through one-time detection, and a new thought is provided for multiple detection of swine disease serology.

The invention relates to a serum marker for predicting glycolipid metabolism and a fat function. The serum marker is FBLN7. As a novel serological marker, the FBLN7 can specifically reflect changes of glycolipid metabolism and fat functions, changes of the serum level of the FBLN7 are closely related to occurrence and development of glycolipid metabolism disorder, and an important basis is provided for early diagnosis of diseases.

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.

The application relates to an AI-assisted result interpretation micro-sample detection kit for cutaneous leishmaniasis infection and an antibody detection method, and belongs to the technical field of serological immunodetection. The kit comprises an antibody detection platform for micro-samples, micro-bead probes, a washing solution, an antibody diluent, F594-labeled sheep anti-rat antibodies, positive quality control serum and negative quality control serum; the spherical probes are adopted in the application, the antigen-antibody combination efficiency is improved in space, and the antigen-antibody collision probability is effectively improved. Meanwhile, the micro-beads form a micro-scale mass transfer network in the reaction cavity, fluid mixing is enhanced, the reaction time is shortened, and the overall residence time and consumption of samples and reagents in the microfluidic channel are reduced. The application also introduces an AI-assisted result interpretation system to assist in result interpretation, significantly improves the friendliness and accessibility of the detection process, the classification model based on artificial intelligence has stronger robustness and judgment consistency, and has good market development value and popularization and application prospect.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

This invention discloses a risk prediction device and storage medium for metabolic-associated fatty liver disease in children or adolescents. The two-stage cascaded screening strategy and model of this invention provide a highly accurate, accessible, and scalable solution for the early identification of metabolic-associated fatty liver disease in children or adolescents. This invention utilizes different anthropometric data to identify high-risk groups in routine school physical examinations, followed by further screening using a comprehensive serological index at community health centers, thereby achieving accurate diagnosis of metabolic-associated fatty liver disease and providing clinicians with a non-invasive auxiliary diagnostic tool that combines high precision, high accuracy, and broad accessibility.

The invention provides a Hunipah virus mRNA vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The mRNA vaccine provided by the invention comprises mRNA attached to glycoprotein of a full-length Hendea virus and an mRNA vaccine delivery system, and serological analysis and a Nipah virus-Malaysia strain and Hendea virus challenge protection experiment prove that the vaccine provided by the invention can generate a very good immune protection effect only by immunizing two doses; the mRNA vaccine has effectiveness on a Nipah virus-Malaysia strain and a Hendea virus at the same time, can protect a subject from lethal infection of the Nipah virus-Malaysia strain and the Hendea virus, and is good in broad spectrum.

The invention relates to an application of lncRNAs Foxo6os in preparation of a medicine for detecting, preventing, relieving and / or treating heart failure. Compared with the prior art, the method has the advantages that the serum sample data of the patient at the early stage of heart failure is included, the exosomes are extracted from the serum in the queue for verification, auxiliary serological indexes are provided for the early diagnosis of the patient at the mental failure, and meanwhile, a novel and powerful biological detection target is provided for the early diagnosis of the heart failure. The result can assist clinicians in early accurate diagnosis and prevention of the heart failure phenotype and pertinently intervene the occurrence of bad outcomes, and also provides an important theoretical basis for the development of targeted drugs.

The invention relates to the technical field of antibodies, and particularly provides an antibody specifically bound with African swine fever virus p34 protein or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO.1 and a light chain variable region as shown in SEQ ID NO.3, and the antibody or the antigen binding fragment thereof can recognize ASFV p34 protein with high specificity. The invention also provides a nucleic acid molecule for coding the antibody or the antigen binding fragment thereof, an expression vector, a recombinant cell and other biological materials. The antibody or the antigen binding fragment thereof can be used for preparing an African swine fever virus detection product, particularly a blocking ELISA antibody detection kit, and the kit has the advantages of high sensitivity, strong specificity, simplicity and convenience in operation and the like, and is suitable for serological monitoring and diagnosis of ASFV. The invention provides an effective detection tool for prevention and control of African swine fever.

The invention discloses a salmonella H: i epitope specific monoclonal antibody and application thereof, the salmonella H: i epitope specific monoclonal antibody is secreted by hybridoma cells with the preservation number of CCTCC NO: C202645, and the antibody has the advantages of high titer and strong specificity. According to the blocking ELISA detection kit constructed by the antibody and the detection method of the blocking ELISA detection kit, the antibody containing H: i antigen epitope salmonella in infected animal serum can be specifically detected, the antibody does not react with antibodies containing no H: i antigen epitope salmonella and non-salmonella, the sensitivity, specificity and stability are good, and the detection method is simple and convenient. And a new method is provided for direct serological detection of H: i antigen epitope-containing salmonella infection of mouse typhimurium, kafenkii and the like.

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

The invention discloses a blood group reagent quality control kit and application thereof, the blood group reagent quality control kit comprises a plurality of independently subpackaged composite quality control products, and each quality control product simultaneously comprises quality control red blood cells with known antigen spectra and quality control plasma with known antibody spectra; the quality control red blood cells are human red blood cells with known ABO blood type, RhD blood type and Rh haplotype; the quality control plasma contains blood group antibodies with known specificity and immune globulin types, and the blood group antibodies comprise IgM antibodies and / or IgG antibodies. The invention also discloses application of the blood group reagent quality control kit in indoor quality control of blood group serology detection and an indoor quality control method of blood group serology detection. The kit provided by the invention can realize integrated and efficient detection, and synchronously complete indoor quality control of a plurality of core items such as blood type identification, antibody screening, cross matching of blood and the like.

The invention discloses a breast cancer postoperative recurrence risk prediction modeling algorithm based on serological markers, aims to realize non-invasive evaluation of breast cancer postoperative recurrence risk by analyzing serological markers detected in different postoperative periods of a patient to construct a prediction model, and relates to the technical field of breast cancer prediction. The method comprises the following steps of data acquisition and preprocessing, data quality control and arrangement, multi-cycle time sequence alignment and feature extraction, dynamic causal convolutional network modeling, and risk prediction and verification. According to the method, serological marker data detected in different postoperative periods of a patient is collected and finely preprocessed, an improved algorithm is utilized to align a time sequence and extract features, a specific convolutional network and a proportional risk model are constructed, and the relationship between serological marker features in different periods and postoperative recurrence of breast cancer is accurately mined; the breast cancer recurrence risk can be predicted more accurately, the clinical verification module visually presents the risk, and the scientificity and practicability of breast cancer recurrence prediction are greatly improved.